gustavo-frazao-shutterstock-com-patent-

Gustavo Frazao / Shutterstock.com

16 March 2016Americas

PTAB gives green light to four Acorda IPR trials

The Patent Trial and Appeal Board (PTAB) has instituted trials on four patents owned by Acorda Therapeutics following challenges from the Coalition for Affordable Drugs and hedge fund manager Kyle Bass.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Acorda hits back at Kyle Bass IPR

28 May 2015 Acorda Therapeutics, the first company to be targeted through an inter partes review filed by US hedge fund manager Kyle Bass, has asked the US Patent and Trademark Office to reject the petition.

Kyle Bass Ampyra IPR challenge is ‘harassment’, says Acorda

16 December 2015 Biotechnology company Acorda Therapeutics has urged the Patent Trial and Appeal Board not to institute an inter partes review petition filed by the Coalition for Affordable Drugs, an organisation linked to hedge fund manager Kyle Bass.

More on this story

Acorda hits back at Kyle Bass IPR

28 May 2015 Acorda Therapeutics, the first company to be targeted through an inter partes review filed by US hedge fund manager Kyle Bass, has asked the US Patent and Trademark Office to reject the petition.

Kyle Bass Ampyra IPR challenge is ‘harassment’, says Acorda

16 December 2015 Biotechnology company Acorda Therapeutics has urged the Patent Trial and Appeal Board not to institute an inter partes review petition filed by the Coalition for Affordable Drugs, an organisation linked to hedge fund manager Kyle Bass.

More on this story

Acorda hits back at Kyle Bass IPR

28 May 2015 Acorda Therapeutics, the first company to be targeted through an inter partes review filed by US hedge fund manager Kyle Bass, has asked the US Patent and Trademark Office to reject the petition.

Kyle Bass Ampyra IPR challenge is ‘harassment’, says Acorda

16 December 2015 Biotechnology company Acorda Therapeutics has urged the Patent Trial and Appeal Board not to institute an inter partes review petition filed by the Coalition for Affordable Drugs, an organisation linked to hedge fund manager Kyle Bass.

More features

Court denies Regeneron bid to halt copy of blockbuster eye drug

Interview: Klaus Grabinski, UPC Court of Appeal president

Gilead scores win in fake HIV drug dispute

Polsinelli grows roster with ex-corporate counsel

‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird

Sandoz wins $137.2m payout for lost profits in generic launch

Sanofi signs global rights deal to develop rare cancer therapy

Unified Patent Court visualised: Cases, divisions, and classes in charts